An Open-Label, Multicenter Study to Evaluate Continued Safety of FB-401 for up to 48 Weeks in Children, Adolescent and Adult Subjects (Ages 2 Years and Older) With Mild to Moderate Atopic Dermatitis Previously Enrolled in FB401-01 Phase 2 Study
Latest Information Update: 01 Nov 2021
At a glance
- Drugs FB-401 (Primary)
- Indications Atopic dermatitis
- Focus Adverse reactions
- Sponsors Forte Biosciences
Most Recent Events
- 22 Oct 2021 Status changed from recruiting to discontinued.(Reason the study was stopped:Failure of the Phase 2 study (protocol FB401-01) to meet its endpoint.).
- 28 Jun 2021 New trial record